Mostrar el registro sencillo del documento
COVID-19 convalescent plasma composition and immunological effects in severe patients
dc.creator | YenyAcosta-Ampudia | |
dc.creator | Diana M.Monsalve | |
dc.creator | Manuel Rojas | |
dc.creator | Yhojan Rodríguez | |
dc.creator | Juan Esteban Gallo | |
dc.creator | Juan Carlos Salazar-Uribe | |
dc.creator | María José Santander | |
dc.creator | Mónica P.Cala | |
dc.creator | Wildeman Zapata | |
dc.creator | María Isabel Zapata | |
dc.creator | Rubén Manrique | |
dc.creator | Pardo Oviedo, Juan Mauricio | |
dc.creator | Bernardo Camacho | |
dc.creator | Carolina Ramírez-Santana | |
dc.creator | Anaya, Juan Manuel | |
dc.creator | CP-COVID-19 group | |
dc.date.accessioned | 2021-01-25T22:03:48Z | |
dc.date.available | 2021-01-25T22:03:48Z | |
dc.date.created | 2021-01 | |
dc.identifier.issn | 1095-9157 | spa |
dc.identifier.uri | http://repositorio.mederi.com.co/handle/123456789/551 | |
dc.description | - | spa |
dc.description.abstract | Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti–IFN–α antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4+ (P < 0.05) and activated and effector CD8+ (P < 0.01) T cells and naïve B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4+ T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-γ (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies. | spa |
dc.format.mimetype | application/pdf | spa |
dc.relation.uri | https://www.sciencedirect.com/science/article/pii/S0896841121000068#! | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | * |
dc.subject | COVID-19 | spa |
dc.title | COVID-19 convalescent plasma composition and immunological effects in severe patients | spa |
dc.subject.keyword | Convalescent plasma | spa |
dc.subject.keyword | COVID-19 | spa |
dc.subject.keyword | Memory cells | spa |
dc.subject.keyword | Cytokines | spa |
dc.subject.keyword | Autoantibodies | spa |
dc.subject.keyword | Metabolomic profile | spa |
dc.rights.accessRights | openAccess | spa |
dc.type.hasVersion | acceptedVersion | spa |
Archivos en el documento
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este documento. |
Este documento aparece en la(s) siguiente(s) colección(ones)
-
Investigación clínica [389]